NRAS and acute myeloid leukemia: Here we utilized four patient derived AML cell lines (MOLM-13 (FLT3-IDT/MLL-AF9), THP-1 (MLL-AF9/TP53), Kasumi-1 (AML-ETO/TP53/KIT), and HL-60 (TP53/NRAS)) and 4 independent samples from primary mononuclear PB of AML patients (2 de novo, 2 relapse; Supplementary Table 1), and infected them with lentivirus expressing shRNAs against either a non-targeting control (shNTC) or shFBXO21 to silence FBXO21 expression (Fig. 2 and Supplementary Fig. 1).